Proteomic analysis identifies the RNA helicase DDX3X as a host target against SARS-CoV-2 infection
Antiviral Res. 2021 Mar 26;190:105064. doi: 10.1016/j.antiviral.2021.105064. Online ahead of print.ABSTRACTCOVID-19 is currently a highly pressing health threat and therapeutic strategies to mitigate the infection impact are urgently needed. Characterization of the SARS-CoV-2 interactome in infected cells may represent a powerful tool to identify cellular proteins hijacked by viruses for their life cycle and develop host-oriented antiviral therapeutics. Here we report the proteomic characterization of host proteins interacting with SARS-CoV-2 Nucleoprotein in infected Vero E6 cells. We identified 24 high-confidence protein...
Source: Antiviral Research - March 30, 2021 Category: Virology Authors: Fabiola Ciccosanti Martina Di Rienzo Alessandra Romagnoli Francesca Colavita Giulia Refolo Concetta Castilletti Chiara Agrati Annalaura Brai Fabrizio Manetti Lorenzo Botta Maria Rosaria Capobianchi Giuseppe Ippolito Mauro Piacentini Gian Maria Fimia Source Type: research

Proteomic analysis identifies the RNA helicase DDX3X as a host target against SARS-CoV-2 infection
Antiviral Res. 2021 Mar 26;190:105064. doi: 10.1016/j.antiviral.2021.105064. Online ahead of print.ABSTRACTCOVID-19 is currently a highly pressing health threat and therapeutic strategies to mitigate the infection impact are urgently needed. Characterization of the SARS-CoV-2 interactome in infected cells may represent a powerful tool to identify cellular proteins hijacked by viruses for their life cycle and develop host-oriented antiviral therapeutics. Here we report the proteomic characterization of host proteins interacting with SARS-CoV-2 Nucleoprotein in infected Vero E6 cells. We identified 24 high-confidence protein...
Source: Antiviral Research - March 30, 2021 Category: Virology Authors: Fabiola Ciccosanti Martina Di Rienzo Alessandra Romagnoli Francesca Colavita Giulia Refolo Concetta Castilletti Chiara Agrati Annalaura Brai Fabrizio Manetti Lorenzo Botta Maria Rosaria Capobianchi Giuseppe Ippolito Mauro Piacentini Gian Maria Fimia Source Type: research

Proteomic analysis identifies the RNA helicase DDX3X as a host target against SARS-CoV-2 infection
Antiviral Res. 2021 Mar 26;190:105064. doi: 10.1016/j.antiviral.2021.105064. Online ahead of print.ABSTRACTCOVID-19 is currently a highly pressing health threat and therapeutic strategies to mitigate the infection impact are urgently needed. Characterization of the SARS-CoV-2 interactome in infected cells may represent a powerful tool to identify cellular proteins hijacked by viruses for their life cycle and develop host-oriented antiviral therapeutics. Here we report the proteomic characterization of host proteins interacting with SARS-CoV-2 Nucleoprotein in infected Vero E6 cells. We identified 24 high-confidence protein...
Source: Antiviral Research - March 30, 2021 Category: Virology Authors: Fabiola Ciccosanti Martina Di Rienzo Alessandra Romagnoli Francesca Colavita Giulia Refolo Concetta Castilletti Chiara Agrati Annalaura Brai Fabrizio Manetti Lorenzo Botta Maria Rosaria Capobianchi Giuseppe Ippolito Mauro Piacentini Gian Maria Fimia Source Type: research

Proteomic analysis identifies the RNA helicase DDX3X as a host target against SARS-CoV-2 infection
Antiviral Res. 2021 Mar 26;190:105064. doi: 10.1016/j.antiviral.2021.105064. Online ahead of print.ABSTRACTCOVID-19 is currently a highly pressing health threat and therapeutic strategies to mitigate the infection impact are urgently needed. Characterization of the SARS-CoV-2 interactome in infected cells may represent a powerful tool to identify cellular proteins hijacked by viruses for their life cycle and develop host-oriented antiviral therapeutics. Here we report the proteomic characterization of host proteins interacting with SARS-CoV-2 Nucleoprotein in infected Vero E6 cells. We identified 24 high-confidence protein...
Source: Antiviral Research - March 30, 2021 Category: Virology Authors: Fabiola Ciccosanti Martina Di Rienzo Alessandra Romagnoli Francesca Colavita Giulia Refolo Concetta Castilletti Chiara Agrati Annalaura Brai Fabrizio Manetti Lorenzo Botta Maria Rosaria Capobianchi Giuseppe Ippolito Mauro Piacentini Gian Maria Fimia Source Type: research

Proteomic analysis identifies the RNA helicase DDX3X as a host target against SARS-CoV-2 infection
Antiviral Res. 2021 Mar 26;190:105064. doi: 10.1016/j.antiviral.2021.105064. Online ahead of print.ABSTRACTCOVID-19 is currently a highly pressing health threat and therapeutic strategies to mitigate the infection impact are urgently needed. Characterization of the SARS-CoV-2 interactome in infected cells may represent a powerful tool to identify cellular proteins hijacked by viruses for their life cycle and develop host-oriented antiviral therapeutics. Here we report the proteomic characterization of host proteins interacting with SARS-CoV-2 Nucleoprotein in infected Vero E6 cells. We identified 24 high-confidence protein...
Source: Antiviral Research - March 30, 2021 Category: Virology Authors: Fabiola Ciccosanti Martina Di Rienzo Alessandra Romagnoli Francesca Colavita Giulia Refolo Concetta Castilletti Chiara Agrati Annalaura Brai Fabrizio Manetti Lorenzo Botta Maria Rosaria Capobianchi Giuseppe Ippolito Mauro Piacentini Gian Maria Fimia Source Type: research

Proteomic Analysis Identifies the RNA Helicase DDX3X as a Host Target Against SARS-CoV-2 Infection
Antiviral Res. 2021 Mar 26;190:105064. doi: 10.1016/j.antiviral.2021.105064. Online ahead of print.ABSTRACTCOVID-19 is currently a highly pressing health threat and therapeutic strategies to mitigate the infection impact are urgently needed. Characterization of the SARS-CoV-2 interactome in infected cells may represent a powerful tool to identify cellular proteins hijacked by viruses for their life cycle and develop host-oriented antiviral therapeutics. Here we report the proteomic characterization of host proteins interacting with SARS-CoV-2 Nucleoprotein in infected Vero E6 cells. We identified 24 high-confidence protein...
Source: Antiviral Research - March 30, 2021 Category: Virology Authors: Fabiola Ciccosanti Martina Di Rienzo Alessandra Romagnoli Francesca Colavita Giulia Refolo Concetta Castilletti Chiara Agrati Annalaura Brai Fabrizio Manetti Lorenzo Botta Maria Rosaria Capobianchi Giuseppe Ippolito Mauro Piacentini Gian Maria Fimia Source Type: research

Proteomic Analysis Identifies the RNA Helicase DDX3X as a Host Target Against SARS-CoV-2 Infection
Antiviral Res. 2021 Mar 26;190:105064. doi: 10.1016/j.antiviral.2021.105064. Online ahead of print.ABSTRACTCOVID-19 is currently a highly pressing health threat and therapeutic strategies to mitigate the infection impact are urgently needed. Characterization of the SARS-CoV-2 interactome in infected cells may represent a powerful tool to identify cellular proteins hijacked by viruses for their life cycle and develop host-oriented antiviral therapeutics. Here we report the proteomic characterization of host proteins interacting with SARS-CoV-2 Nucleoprotein in infected Vero E6 cells. We identified 24 high-confidence protein...
Source: Antiviral Research - March 30, 2021 Category: Virology Authors: Fabiola Ciccosanti Martina Di Rienzo Alessandra Romagnoli Francesca Colavita Giulia Refolo Concetta Castilletti Chiara Agrati Annalaura Brai Fabrizio Manetti Lorenzo Botta Maria Rosaria Capobianchi Giuseppe Ippolito Mauro Piacentini Gian Maria Fimia Source Type: research

Proteomic Analysis Identifies the RNA Helicase DDX3X as a Host Target Against SARS-CoV-2 Infection
Antiviral Res. 2021 Mar 26:105064. doi: 10.1016/j.antiviral.2021.105064. Online ahead of print.ABSTRACTCOVID-19 is currently a highly pressing health threat and therapeutic strategies to mitigate the infection impact are urgently needed. Characterization of the SARS-CoV-2 interactome in infected cells may represent a powerful tool to identify cellular proteins hijacked by viruses for their life cycle and develop host-oriented antiviral therapeutics. Here we report the proteomic characterization of host proteins interacting with SARS-CoV-2 Nucleoprotein in infected Vero E6 cells. We identified 24 high-confidence proteins ma...
Source: Antiviral Research - March 30, 2021 Category: Virology Authors: Fabiola Ciccosanti Martina Di Rienzo Alessandra Romagnoli Francesca Colavita Giulia Refolo Concetta Castilletti Chiara Agrati Annalaura Brai Fabrizio Manetti Lorenzo Botta Maria Rosaria Capobianchi Giuseppe Ippolito Mauro Piacentini Gian Maria Fimia Source Type: research

Proteomic Analysis Identifies the RNA Helicase DDX3X as a Host Target Against SARS-CoV-2 Infection
Antiviral Res. 2021 Mar 26:105064. doi: 10.1016/j.antiviral.2021.105064. Online ahead of print.ABSTRACTCOVID-19 is currently a highly pressing health threat and therapeutic strategies to mitigate the infection impact are urgently needed. Characterization of the SARS-CoV-2 interactome in infected cells may represent a powerful tool to identify cellular proteins hijacked by viruses for their life cycle and develop host-oriented antiviral therapeutics. Here we report the proteomic characterization of host proteins interacting with SARS-CoV-2 Nucleoprotein in infected Vero E6 cells. We identified 24 high-confidence proteins ma...
Source: Antiviral Research - March 30, 2021 Category: Virology Authors: Fabiola Ciccosanti Martina Di Rienzo Alessandra Romagnoli Francesca Colavita Giulia Refolo Concetta Castilletti Chiara Agrati Annalaura Brai Fabrizio Manetti Lorenzo Botta Maria Rosaria Capobianchi Giuseppe Ippolito Mauro Piacentini Gian Maria Fimia Source Type: research

Proteomic Analysis Identifies the RNA Helicase DDX3X as a Host Target Against SARS-CoV-2 Infection
Antiviral Res. 2021 Mar 26:105064. doi: 10.1016/j.antiviral.2021.105064. Online ahead of print.ABSTRACTCOVID-19 is currently a highly pressing health threat and therapeutic strategies to mitigate the infection impact are urgently needed. Characterization of the SARS-CoV-2 interactome in infected cells may represent a powerful tool to identify cellular proteins hijacked by viruses for their life cycle and develop host-oriented antiviral therapeutics. Here we report the proteomic characterization of host proteins interacting with SARS-CoV-2 Nucleoprotein in infected Vero E6 cells. We identified 24 high-confidence proteins ma...
Source: Antiviral Research - March 30, 2021 Category: Virology Authors: Fabiola Ciccosanti Martina Di Rienzo Alessandra Romagnoli Francesca Colavita Giulia Refolo Concetta Castilletti Chiara Agrati Annalaura Brai Fabrizio Manetti Lorenzo Botta Maria Rosaria Capobianchi Giuseppe Ippolito Mauro Piacentini Gian Maria Fimia Source Type: research

Proteomic Analysis Identifies the RNA Helicase DDX3X as a Host Target Against SARS-CoV-2 Infection
Antiviral Res. 2021 Mar 26:105064. doi: 10.1016/j.antiviral.2021.105064. Online ahead of print.ABSTRACTCOVID-19 is currently a highly pressing health threat and therapeutic strategies to mitigate the infection impact are urgently needed. Characterization of the SARS-CoV-2 interactome in infected cells may represent a powerful tool to identify cellular proteins hijacked by viruses for their life cycle and develop host-oriented antiviral therapeutics. Here we report the proteomic characterization of host proteins interacting with SARS-CoV-2 Nucleoprotein in infected Vero E6 cells. We identified 24 high-confidence proteins ma...
Source: Antiviral Research - March 30, 2021 Category: Virology Authors: Fabiola Ciccosanti Martina Di Rienzo Alessandra Romagnoli Francesca Colavita Giulia Refolo Concetta Castilletti Chiara Agrati Annalaura Brai Fabrizio Manetti Lorenzo Botta Maria Rosaria Capobianchi Giuseppe Ippolito Mauro Piacentini Gian Maria Fimia Source Type: research

Proteomic Analysis Identifies the RNA Helicase DDX3X as a Host Target Against SARS-CoV-2 Infection
Antiviral Res. 2021 Mar 26:105064. doi: 10.1016/j.antiviral.2021.105064. Online ahead of print.ABSTRACTCOVID-19 is currently a highly pressing health threat and therapeutic strategies to mitigate the infection impact are urgently needed. Characterization of the SARS-CoV-2 interactome in infected cells may represent a powerful tool to identify cellular proteins hijacked by viruses for their life cycle and develop host-oriented antiviral therapeutics. Here we report the proteomic characterization of host proteins interacting with SARS-CoV-2 Nucleoprotein in infected Vero E6 cells. We identified 24 high-confidence proteins ma...
Source: Antiviral Research - March 30, 2021 Category: Virology Authors: Fabiola Ciccosanti Martina Di Rienzo Alessandra Romagnoli Francesca Colavita Giulia Refolo Concetta Castilletti Chiara Agrati Annalaura Brai Fabrizio Manetti Lorenzo Botta Maria Rosaria Capobianchi Giuseppe Ippolito Mauro Piacentini Gian Maria Fimia Source Type: research

Proteomic Analysis Identifies the RNA Helicase DDX3X as a Host Target Against SARS-CoV-2 Infection
Antiviral Res. 2021 Mar 26:105064. doi: 10.1016/j.antiviral.2021.105064. Online ahead of print.ABSTRACTCOVID-19 is currently a highly pressing health threat and therapeutic strategies to mitigate the infection impact are urgently needed. Characterization of the SARS-CoV-2 interactome in infected cells may represent a powerful tool to identify cellular proteins hijacked by viruses for their life cycle and develop host-oriented antiviral therapeutics. Here we report the proteomic characterization of host proteins interacting with SARS-CoV-2 Nucleoprotein in infected Vero E6 cells. We identified 24 high-confidence proteins ma...
Source: Antiviral Research - March 30, 2021 Category: Virology Authors: Fabiola Ciccosanti Martina Di Rienzo Alessandra Romagnoli Francesca Colavita Giulia Refolo Concetta Castilletti Chiara Agrati Annalaura Brai Fabrizio Manetti Lorenzo Botta Maria Rosaria Capobianchi Giuseppe Ippolito Mauro Piacentini Gian Maria Fimia Source Type: research

Sildenafil prevents HDACi-induced Epstein-Barr virus reactivation through the PKG pathway in NK/T cell lymphoma; potential implications for HDACi-mediated fatal complications
Antiviral Res. 2021 Mar 16:105063. doi: 10.1016/j.antiviral.2021.105063. Online ahead of print.ABSTRACTRomidepsin, a histone deacetylase (HDAC) inhibitor, has been approved for the treatment of relapsed and refractory peripheral T-cell lymphoma. However the use of romidepsin reportedly causes potent EBV (Epstein-Barr virus) reactivation leading to severe adverse events in patients with natural killer (NK)/T-cell lymphoma (NKTL). As inhibition of EBV lytic cycle reactivation may help prevent romidepsin-induced adverse events in NKTL, we herein set out to identify a safe and effective drug for inhibiting EBV reactivation and...
Source: Antiviral Research - March 20, 2021 Category: Virology Authors: Joo Hyun Kim Won Seog Kim Chaehwa Park Source Type: research

Sildenafil prevents HDACi-induced Epstein-Barr virus reactivation through the PKG pathway in NK/T cell lymphoma; potential implications for HDACi-mediated fatal complications
Antiviral Res. 2021 Mar 16:105063. doi: 10.1016/j.antiviral.2021.105063. Online ahead of print.ABSTRACTRomidepsin, a histone deacetylase (HDAC) inhibitor, has been approved for the treatment of relapsed and refractory peripheral T-cell lymphoma. However the use of romidepsin reportedly causes potent EBV (Epstein-Barr virus) reactivation leading to severe adverse events in patients with natural killer (NK)/T-cell lymphoma (NKTL). As inhibition of EBV lytic cycle reactivation may help prevent romidepsin-induced adverse events in NKTL, we herein set out to identify a safe and effective drug for inhibiting EBV reactivation and...
Source: Antiviral Research - March 20, 2021 Category: Virology Authors: Joo Hyun Kim Won Seog Kim Chaehwa Park Source Type: research

Sildenafil prevents HDACi-induced Epstein-Barr virus reactivation through the PKG pathway in NK/T cell lymphoma; potential implications for HDACi-mediated fatal complications
Antiviral Res. 2021 Mar 16:105063. doi: 10.1016/j.antiviral.2021.105063. Online ahead of print.ABSTRACTRomidepsin, a histone deacetylase (HDAC) inhibitor, has been approved for the treatment of relapsed and refractory peripheral T-cell lymphoma. However the use of romidepsin reportedly causes potent EBV (Epstein-Barr virus) reactivation leading to severe adverse events in patients with natural killer (NK)/T-cell lymphoma (NKTL). As inhibition of EBV lytic cycle reactivation may help prevent romidepsin-induced adverse events in NKTL, we herein set out to identify a safe and effective drug for inhibiting EBV reactivation and...
Source: Antiviral Research - March 20, 2021 Category: Virology Authors: Joo Hyun Kim Won Seog Kim Chaehwa Park Source Type: research

Sildenafil prevents HDACi-induced Epstein-Barr virus reactivation through the PKG pathway in NK/T cell lymphoma; potential implications for HDACi-mediated fatal complications
Antiviral Res. 2021 Mar 16:105063. doi: 10.1016/j.antiviral.2021.105063. Online ahead of print.ABSTRACTRomidepsin, a histone deacetylase (HDAC) inhibitor, has been approved for the treatment of relapsed and refractory peripheral T-cell lymphoma. However the use of romidepsin reportedly causes potent EBV (Epstein-Barr virus) reactivation leading to severe adverse events in patients with natural killer (NK)/T-cell lymphoma (NKTL). As inhibition of EBV lytic cycle reactivation may help prevent romidepsin-induced adverse events in NKTL, we herein set out to identify a safe and effective drug for inhibiting EBV reactivation and...
Source: Antiviral Research - March 20, 2021 Category: Virology Authors: Joo Hyun Kim Won Seog Kim Chaehwa Park Source Type: research

Sildenafil prevents HDACi-induced Epstein-Barr virus reactivation through the PKG pathway in NK/T cell lymphoma; potential implications for HDACi-mediated fatal complications
Antiviral Res. 2021 Mar 16:105063. doi: 10.1016/j.antiviral.2021.105063. Online ahead of print.ABSTRACTRomidepsin, a histone deacetylase (HDAC) inhibitor, has been approved for the treatment of relapsed and refractory peripheral T-cell lymphoma. However the use of romidepsin reportedly causes potent EBV (Epstein-Barr virus) reactivation leading to severe adverse events in patients with natural killer (NK)/T-cell lymphoma (NKTL). As inhibition of EBV lytic cycle reactivation may help prevent romidepsin-induced adverse events in NKTL, we herein set out to identify a safe and effective drug for inhibiting EBV reactivation and...
Source: Antiviral Research - March 20, 2021 Category: Virology Authors: Joo Hyun Kim Won Seog Kim Chaehwa Park Source Type: research

Sildenafil prevents HDACi-induced Epstein-Barr virus reactivation through the PKG pathway in NK/T cell lymphoma; potential implications for HDACi-mediated fatal complications
Antiviral Res. 2021 Mar 16:105063. doi: 10.1016/j.antiviral.2021.105063. Online ahead of print.ABSTRACTRomidepsin, a histone deacetylase (HDAC) inhibitor, has been approved for the treatment of relapsed and refractory peripheral T-cell lymphoma. However the use of romidepsin reportedly causes potent EBV (Epstein-Barr virus) reactivation leading to severe adverse events in patients with natural killer (NK)/T-cell lymphoma (NKTL). As inhibition of EBV lytic cycle reactivation may help prevent romidepsin-induced adverse events in NKTL, we herein set out to identify a safe and effective drug for inhibiting EBV reactivation and...
Source: Antiviral Research - March 20, 2021 Category: Virology Authors: Joo Hyun Kim Won Seog Kim Chaehwa Park Source Type: research

Sildenafil prevents HDACi-induced Epstein-Barr virus reactivation through the PKG pathway in NK/T cell lymphoma; potential implications for HDACi-mediated fatal complications
Antiviral Res. 2021 Mar 16:105063. doi: 10.1016/j.antiviral.2021.105063. Online ahead of print.ABSTRACTRomidepsin, a histone deacetylase (HDAC) inhibitor, has been approved for the treatment of relapsed and refractory peripheral T-cell lymphoma. However the use of romidepsin reportedly causes potent EBV (Epstein-Barr virus) reactivation leading to severe adverse events in patients with natural killer (NK)/T-cell lymphoma (NKTL). As inhibition of EBV lytic cycle reactivation may help prevent romidepsin-induced adverse events in NKTL, we herein set out to identify a safe and effective drug for inhibiting EBV reactivation and...
Source: Antiviral Research - March 20, 2021 Category: Virology Authors: Joo Hyun Kim Won Seog Kim Chaehwa Park Source Type: research

Sildenafil prevents HDACi-induced Epstein-Barr virus reactivation through the PKG pathway in NK/T cell lymphoma; potential implications for HDACi-mediated fatal complications
Antiviral Res. 2021 Mar 16:105063. doi: 10.1016/j.antiviral.2021.105063. Online ahead of print.ABSTRACTRomidepsin, a histone deacetylase (HDAC) inhibitor, has been approved for the treatment of relapsed and refractory peripheral T-cell lymphoma. However the use of romidepsin reportedly causes potent EBV (Epstein-Barr virus) reactivation leading to severe adverse events in patients with natural killer (NK)/T-cell lymphoma (NKTL). As inhibition of EBV lytic cycle reactivation may help prevent romidepsin-induced adverse events in NKTL, we herein set out to identify a safe and effective drug for inhibiting EBV reactivation and...
Source: Antiviral Research - March 20, 2021 Category: Virology Authors: Joo Hyun Kim Won Seog Kim Chaehwa Park Source Type: research

The Antifungal Drug Isavuconazole Inhibits the Replication of Human Cytomegalovirus (HCMV) and Acts Synergistically with Anti-HCMV Drugs
Antiviral Res. 2021 Mar 12:105062. doi: 10.1016/j.antiviral.2021.105062. Online ahead of print.ABSTRACTWe recently reported that some clinically approved antifungal drugs are potent inhibitors of human cytomegalovirus (HCMV). Here, we report the broad-spectrum activity against HCMV of isavuconazole (ICZ), a new extended-spectrum triazolic antifungal drug. ICZ inhibited the replication of clinical isolates of HCMV as well as strains resistant to the currently available DNA polymerase inhibitors. The antiviral activity of ICZ against HCMV could be linked to the inhibition of human cytochrome P450 51 (hCYP51), an enzyme whose...
Source: Antiviral Research - March 16, 2021 Category: Virology Authors: Beatrice Mercorelli Marta Celegato Anna Luganini Giorgio Gribaudo Galina I Lepesheva Arianna Loregian Source Type: research

The Antifungal Drug Isavuconazole Inhibits the Replication of Human Cytomegalovirus (HCMV) and Acts Synergistically with Anti-HCMV Drugs
Antiviral Res. 2021 Mar 12:105062. doi: 10.1016/j.antiviral.2021.105062. Online ahead of print.ABSTRACTWe recently reported that some clinically approved antifungal drugs are potent inhibitors of human cytomegalovirus (HCMV). Here, we report the broad-spectrum activity against HCMV of isavuconazole (ICZ), a new extended-spectrum triazolic antifungal drug. ICZ inhibited the replication of clinical isolates of HCMV as well as strains resistant to the currently available DNA polymerase inhibitors. The antiviral activity of ICZ against HCMV could be linked to the inhibition of human cytochrome P450 51 (hCYP51), an enzyme whose...
Source: Antiviral Research - March 16, 2021 Category: Virology Authors: Beatrice Mercorelli Marta Celegato Anna Luganini Giorgio Gribaudo Galina I Lepesheva Arianna Loregian Source Type: research

The Antifungal Drug Isavuconazole Inhibits the Replication of Human Cytomegalovirus (HCMV) and Acts Synergistically with Anti-HCMV Drugs
Antiviral Res. 2021 Mar 12:105062. doi: 10.1016/j.antiviral.2021.105062. Online ahead of print.ABSTRACTWe recently reported that some clinically approved antifungal drugs are potent inhibitors of human cytomegalovirus (HCMV). Here, we report the broad-spectrum activity against HCMV of isavuconazole (ICZ), a new extended-spectrum triazolic antifungal drug. ICZ inhibited the replication of clinical isolates of HCMV as well as strains resistant to the currently available DNA polymerase inhibitors. The antiviral activity of ICZ against HCMV could be linked to the inhibition of human cytochrome P450 51 (hCYP51), an enzyme whose...
Source: Antiviral Research - March 16, 2021 Category: Virology Authors: Beatrice Mercorelli Marta Celegato Anna Luganini Giorgio Gribaudo Galina I Lepesheva Arianna Loregian Source Type: research

The Antifungal Drug Isavuconazole Inhibits the Replication of Human Cytomegalovirus (HCMV) and Acts Synergistically with Anti-HCMV Drugs
Antiviral Res. 2021 Mar 12:105062. doi: 10.1016/j.antiviral.2021.105062. Online ahead of print.ABSTRACTWe recently reported that some clinically approved antifungal drugs are potent inhibitors of human cytomegalovirus (HCMV). Here, we report the broad-spectrum activity against HCMV of isavuconazole (ICZ), a new extended-spectrum triazolic antifungal drug. ICZ inhibited the replication of clinical isolates of HCMV as well as strains resistant to the currently available DNA polymerase inhibitors. The antiviral activity of ICZ against HCMV could be linked to the inhibition of human cytochrome P450 51 (hCYP51), an enzyme whose...
Source: Antiviral Research - March 16, 2021 Category: Virology Authors: Beatrice Mercorelli Marta Celegato Anna Luganini Giorgio Gribaudo Galina I Lepesheva Arianna Loregian Source Type: research

Effective deploying of a novel DHODH inhibitor against herpes simplex type 1 and type 2 replication
Antiviral Res. 2021 Mar 11:105057. doi: 10.1016/j.antiviral.2021.105057. Online ahead of print.ABSTRACTEmergence of drug resistance and adverse effects often affect the efficacy of nucleoside analogues in the therapy of Herpes simplex type 1 (HSV-1) and type 2 (HSV-2) infections. Host-targeting antivirals could therefore be considered as an alternative or complementary strategy in the management of HSV infections. To contribute to this advancement, here we report on the ability of a new generation inhibitor of a key cellular enzyme of de novo pyrimidine biosynthesis, the dihydroorotate dehydrogenase (DHODH), to inhibit HSV...
Source: Antiviral Research - March 15, 2021 Category: Virology Authors: Anna Luganini Giulia Sibille Barbara Mognetti Stefano Sainas Agnese Chiara Pippione Marta Giorgis Donatella Boschi Marco L Lolli Giorgio Gribaudo Source Type: research

Effective deploying of a novel DHODH inhibitor against herpes simplex type 1 and type 2 replication
Antiviral Res. 2021 Mar 11:105057. doi: 10.1016/j.antiviral.2021.105057. Online ahead of print.ABSTRACTEmergence of drug resistance and adverse effects often affect the efficacy of nucleoside analogues in the therapy of Herpes simplex type 1 (HSV-1) and type 2 (HSV-2) infections. Host-targeting antivirals could therefore be considered as an alternative or complementary strategy in the management of HSV infections. To contribute to this advancement, here we report on the ability of a new generation inhibitor of a key cellular enzyme of de novo pyrimidine biosynthesis, the dihydroorotate dehydrogenase (DHODH), to inhibit HSV...
Source: Antiviral Research - March 15, 2021 Category: Virology Authors: Anna Luganini Giulia Sibille Barbara Mognetti Stefano Sainas Agnese Chiara Pippione Marta Giorgis Donatella Boschi Marco L Lolli Giorgio Gribaudo Source Type: research

Combined in silico and in vitro approaches identified the antipsychotic drug lurasidone and the antiviral drug elbasvir as SARS-CoV2 and HCoV-OC43 inhibitors
Antiviral Res. 2021 Mar 10:105055. doi: 10.1016/j.antiviral.2021.105055. Online ahead of print.ABSTRACTThe current emergency of the novel coronavirus SARS-CoV2 urged the need for broad-spectrum antiviral drugs as the first line of treatment. Coronaviruses are a large family of viruses that already challenged humanity in at least two other previous outbreaks and are likely to be a constant threat for the future. In this work we developed a pipeline based on in silico docking of known drugs on SARS-CoV1 and 2 RNA-dependent RNA polymerase combined with in vitro antiviral assays on both SARS-CoV2 and the common cold human coro...
Source: Antiviral Research - March 13, 2021 Category: Virology Authors: Mario Milani Manuela Donalisio Rafaela Milan Bonotto Edoardo Schneider Irene Arduino Francesco Boni David Lembo Alessandro Marcello Eloise Mastrangelo Source Type: research

Secondary substitutions in the hemagglutinin and neuraminidase genes associated with neuraminidase inhibitor resistance are rare in the Influenza Resistance Information Study (IRIS)
Antiviral Res. 2021 Mar 10:105060. doi: 10.1016/j.antiviral.2021.105060. Online ahead of print.ABSTRACTAmino acid substitutions in influenza virus neuraminidase (NA) that cause resistance to neuraminidase inhibitors (NAI) generally result in virus attenuation. However, influenza viruses may acquire secondary substitutions in the NA and hemagglutinin (HA) proteins that can restore viral fitness. To assess to which extent this happens, the emergence of NAI resistance substitutions and secondary - potentially compensatory - substitutions was quantified in influenza viruses of immunocompetent individuals included in the Influe...
Source: Antiviral Research - March 13, 2021 Category: Virology Authors: Rueshandra Roosenhoff Martin Schutten Vaughan Reed Barry Clinch Anne van der Linden Ron A M Fouchier Pieter L A Fraaij Source Type: research

Emetine suppresses SARS-CoV-2 replication by inhibiting interaction of viral mRNA with eIF4E
In this study, we evaluated the in vitro antiviral efficacy of emetine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and found it to be a low nanomolar (nM) inhibitor. Interestingly, emetine exhibited protective efficacy against lethal challenge with infectious bronchitis virus (IBV; a chicken coronavirus) in the embryonated chicken egg infection model. Emetine treatment led to a decrease in viral RNA and protein synthesis without affecting other steps of viral life cycle such as attachment, entry and budding. In a chromatin immunoprecipitation (CHIP) assay, emetine was shown to disrupt the binding o...
Source: Antiviral Research - March 12, 2021 Category: Virology Authors: Ram Kumar Mohammad Afsar Nitin Khandelwal Yogesh Chander Thachamvally Riyesh Ramesh Kumar Dedar Baldev R Gulati Yash Pal Sanjay Barua Bhupendra N Tripathi Tanweer Hussain Naveen Kumar Source Type: research

Methodology-dependent performance of serum HBV RNA in predicting treatment outcomes in chronic hepatitis B patients
CONCLUSION: The outcome prediction performance of serum HBV RNAs is methodology-dependent. PolyA-RNA detection was not recommended to predict off-treatment relapses.PMID:33711337 | DOI:10.1016/j.antiviral.2021.105037 (Source: Antiviral Research)
Source: Antiviral Research - March 12, 2021 Category: Virology Authors: Shi Liu Yaobo Wu Rui Deng Sheng Shen Rong Fan Jie Peng Wanying Li Xieer Liang Jinlin Hou Jian Sun Bin Zhou Source Type: research

Investigation of multidrug-resistance mutations of hepatitis B virus (HBV) in a large cohort of chronic HBV-infected patients with treatment of nucleoside/nucleotide analogs
Antiviral Res. 2021 Mar 9:105058. doi: 10.1016/j.antiviral.2021.105058. Online ahead of print.ABSTRACTMultidrug-resistance hepatitis B virus (MDR HBV), defined as those with mutations resistant to both nucleoside analogs lamivudine/telbivudine/entecavir (LAM/LdT/ETV) and nucleotide analog adefovir (ADV), has potential to cause treatment difficulty. To clarify clinical prevalence and virological features of MDR HBV, we investigated serum samples from 28,236 chronic HBV-infected patients with treatment of nucleoside/nucleotide analogs. All patients underwent resistance testing in the Fifth Medical Center of Chinese PLA Gener...
Source: Antiviral Research - March 12, 2021 Category: Virology Authors: Yan Liu Rongjuan Chen Wenhui Liu Lanlan Si Le Li Xiaodong Li None ZengtaoYao Hao Liao Jun Wang Yuanhua Li Jun Zhao Dongping Xu Source Type: research

Emetine suppresses SARS-CoV-2 replication by inhibiting interaction of viral mRNA with eIF4E
In this study, we evaluated the in vitro antiviral efficacy of emetine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and found it to be a low nanomolar (nM) inhibitor. Interestingly, emetine exhibited protective efficacy against lethal challenge with infectious bronchitis virus (IBV; a chicken coronavirus) in the embryonated chicken egg infection model. Emetine treatment led to a decrease in viral RNA and protein synthesis without affecting other steps of viral life cycle such as attachment, entry and budding. In a chromatin immunoprecipitation (CHIP) assay, emetine was shown to disrupt the binding o...
Source: Antiviral Research - March 12, 2021 Category: Virology Authors: Ram Kumar Mohammad Afsar Nitin Khandelwal Yogesh Chander Thachamvally Riyesh Ramesh Kumar Dedar Baldev R Gulati Yash Pal Sanjay Barua Bhupendra N Tripathi Tanweer Hussain Naveen Kumar Source Type: research

Methodology-dependent performance of serum HBV RNA in predicting treatment outcomes in chronic hepatitis B patients
CONCLUSION: The outcome prediction performance of serum HBV RNAs is methodology-dependent. PolyA-RNA detection was not recommended to predict off-treatment relapses.PMID:33711337 | DOI:10.1016/j.antiviral.2021.105037 (Source: Antiviral Research)
Source: Antiviral Research - March 12, 2021 Category: Virology Authors: Shi Liu Yaobo Wu Rui Deng Sheng Shen Rong Fan Jie Peng Wanying Li Xieer Liang Jinlin Hou Jian Sun Bin Zhou Source Type: research

Investigation of multidrug-resistance mutations of hepatitis B virus (HBV) in a large cohort of chronic HBV-infected patients with treatment of nucleoside/nucleotide analogs
Antiviral Res. 2021 Mar 9:105058. doi: 10.1016/j.antiviral.2021.105058. Online ahead of print.ABSTRACTMultidrug-resistance hepatitis B virus (MDR HBV), defined as those with mutations resistant to both nucleoside analogs lamivudine/telbivudine/entecavir (LAM/LdT/ETV) and nucleotide analog adefovir (ADV), has potential to cause treatment difficulty. To clarify clinical prevalence and virological features of MDR HBV, we investigated serum samples from 28,236 chronic HBV-infected patients with treatment of nucleoside/nucleotide analogs. All patients underwent resistance testing in the Fifth Medical Center of Chinese PLA Gener...
Source: Antiviral Research - March 12, 2021 Category: Virology Authors: Yan Liu Rongjuan Chen Wenhui Liu Lanlan Si Le Li Xiaodong Li None ZengtaoYao Hao Liao Jun Wang Yuanhua Li Jun Zhao Dongping Xu Source Type: research

A novel cell culture model reveals the viral interference during hepatitis B and C coinfection
Conclusions: HepG2-NTCP/CD81/Mir122 fully supports HBV/HCV coinfection, replication and interaction. This novel cell model offers a platform to advance our understanding of the molecular details of the interaction, pathogenesis and outcomes of HBV/HCV coinfection.PMID:33705864 | DOI:10.1016/j.antiviral.2021.105061 (Source: Antiviral Research)
Source: Antiviral Research - March 11, 2021 Category: Virology Authors: Kai Zhang Xinyuan Lai Ji Song Lingyuan He Luwei Wang Guomin Ou Xing Tian Lei Wang Juan Deng Jiajia Zhang Chuanyun Li Hui Zhuang Tong Li Kuanhui Xiang Source Type: research

Identification of Filovirus Entry Inhibitors Targeting the Endosomal Receptor NPC1 Binding Site
In conclusion, this work has identified several qualified lead-compounds for further drug development against filovirus infection.PMID:33705865 | DOI:10.1016/j.antiviral.2021.105059 (Source: Antiviral Research)
Source: Antiviral Research - March 11, 2021 Category: Virology Authors: Leah Liu Wang Nicholas Palermo Leslie Estrada Colton Thompson J J Patten Manu Anantpadma Robert A Davey Shi-Hua Xiang Source Type: research

A novel cell culture model reveals the viral interference during hepatitis B and C coinfection
Conclusions: HepG2-NTCP/CD81/Mir122 fully supports HBV/HCV coinfection, replication and interaction. This novel cell model offers a platform to advance our understanding of the molecular details of the interaction, pathogenesis and outcomes of HBV/HCV coinfection.PMID:33705864 | DOI:10.1016/j.antiviral.2021.105061 (Source: Antiviral Research)
Source: Antiviral Research - March 11, 2021 Category: Virology Authors: Kai Zhang Xinyuan Lai Ji Song Lingyuan He Luwei Wang Guomin Ou Xing Tian Lei Wang Juan Deng Jiajia Zhang Chuanyun Li Hui Zhuang Tong Li Kuanhui Xiang Source Type: research

Identification of Filovirus Entry Inhibitors Targeting the Endosomal Receptor NPC1 Binding Site
In conclusion, this work has identified several qualified lead-compounds for further drug development against filovirus infection.PMID:33705865 | DOI:10.1016/j.antiviral.2021.105059 (Source: Antiviral Research)
Source: Antiviral Research - March 11, 2021 Category: Virology Authors: Leah Liu Wang Nicholas Palermo Leslie Estrada Colton Thompson J J Patten Manu Anantpadma Robert A Davey Shi-Hua Xiang Source Type: research

Corrigendum to "Cetylpyridinium chloride blocks herpes simplex virus replication in gingival fibroblasts" [Anti. Res. 179 (2020) 104818]
Antiviral Res. 2021 Feb 22:105022. doi: 10.1016/j.antiviral.2021.105022. Online ahead of print.NO ABSTRACTPMID:33627248 | DOI:10.1016/j.antiviral.2021.105022 (Source: Antiviral Research)
Source: Antiviral Research - February 25, 2021 Category: Virology Authors: Diana M Alvarez Luisa F Duarte Nicolas Corrales Patricio C Smith Pablo A Gonz ález Source Type: research

Corrigendum to "Cetylpyridinium chloride blocks herpes simplex virus replication in gingival fibroblasts" [Anti. Res. 179 (2020) 104818]
Antiviral Res. 2021 Feb 22:105022. doi: 10.1016/j.antiviral.2021.105022. Online ahead of print.NO ABSTRACTPMID:33627248 | DOI:10.1016/j.antiviral.2021.105022 (Source: Antiviral Research)
Source: Antiviral Research - February 25, 2021 Category: Virology Authors: Diana M Alvarez Luisa F Duarte Nicolas Corrales Patricio C Smith Pablo A Gonz ález Source Type: research

Corrigendum to "Cetylpyridinium chloride blocks herpes simplex virus replication in gingival fibroblasts" [Anti. Res. 179 (2020) 104818]
Antiviral Res. 2021 Feb 22:105022. doi: 10.1016/j.antiviral.2021.105022. Online ahead of print.NO ABSTRACTPMID:33627248 | DOI:10.1016/j.antiviral.2021.105022 (Source: Antiviral Research)
Source: Antiviral Research - February 25, 2021 Category: Virology Authors: Diana M Alvarez Luisa F Duarte Nicolas Corrales Patricio C Smith Pablo A Gonz ález Source Type: research

Corrigendum to "Cetylpyridinium chloride blocks herpes simplex virus replication in gingival fibroblasts" [Anti. Res. 179 (2020) 104818]
Antiviral Res. 2021 Feb 22:105022. doi: 10.1016/j.antiviral.2021.105022. Online ahead of print.NO ABSTRACTPMID:33627248 | DOI:10.1016/j.antiviral.2021.105022 (Source: Antiviral Research)
Source: Antiviral Research - February 25, 2021 Category: Virology Authors: Diana M Alvarez Luisa F Duarte Nicolas Corrales Patricio C Smith Pablo A Gonz ález Source Type: research

Corrigendum to "Cetylpyridinium chloride blocks herpes simplex virus replication in gingival fibroblasts" [Anti. Res. 179 (2020) 104818]
Antiviral Res. 2021 Feb 22:105022. doi: 10.1016/j.antiviral.2021.105022. Online ahead of print.NO ABSTRACTPMID:33627248 | DOI:10.1016/j.antiviral.2021.105022 (Source: Antiviral Research)
Source: Antiviral Research - February 25, 2021 Category: Virology Authors: Diana M Alvarez Luisa F Duarte Nicolas Corrales Patricio C Smith Pablo A Gonz ález Source Type: research

Corrigendum to "Cetylpyridinium chloride blocks herpes simplex virus replication in gingival fibroblasts" [Anti. Res. 179 (2020) 104818]
Antiviral Res. 2021 Feb 22:105022. doi: 10.1016/j.antiviral.2021.105022. Online ahead of print.NO ABSTRACTPMID:33627248 | DOI:10.1016/j.antiviral.2021.105022 (Source: Antiviral Research)
Source: Antiviral Research - February 25, 2021 Category: Virology Authors: Diana M Alvarez Luisa F Duarte Nicolas Corrales Patricio C Smith Pablo A Gonz ález Source Type: research

Corrigendum to "Cetylpyridinium chloride blocks herpes simplex virus replication in gingival fibroblasts" [Anti. Res. 179 (2020) 104818]
Antiviral Res. 2021 Feb 22:105022. doi: 10.1016/j.antiviral.2021.105022. Online ahead of print.NO ABSTRACTPMID:33627248 | DOI:10.1016/j.antiviral.2021.105022 (Source: Antiviral Research)
Source: Antiviral Research - February 25, 2021 Category: Virology Authors: Diana M Alvarez Luisa F Duarte Nicolas Corrales Patricio C Smith Pablo A Gonz ález Source Type: research

Corrigendum to "Cetylpyridinium chloride blocks herpes simplex virus replication in gingival fibroblasts" [Anti. Res. 179 (2020) 104818]
Antiviral Res. 2021 Feb 22:105022. doi: 10.1016/j.antiviral.2021.105022. Online ahead of print.NO ABSTRACTPMID:33627248 | DOI:10.1016/j.antiviral.2021.105022 (Source: Antiviral Research)
Source: Antiviral Research - February 25, 2021 Category: Virology Authors: Diana M Alvarez Luisa F Duarte Nicolas Corrales Patricio C Smith Pablo A Gonz ález Source Type: research

Corrigendum to "Cetylpyridinium chloride blocks herpes simplex virus replication in gingival fibroblasts" [Anti. Res. 179 (2020) 104818]
Antiviral Res. 2021 Feb 22:105022. doi: 10.1016/j.antiviral.2021.105022. Online ahead of print.NO ABSTRACTPMID:33627248 | DOI:10.1016/j.antiviral.2021.105022 (Source: Antiviral Research)
Source: Antiviral Research - February 25, 2021 Category: Virology Authors: Diana M Alvarez Luisa F Duarte Nicolas Corrales Patricio C Smith Pablo A Gonz ález Source Type: research

Corrigendum to "Cetylpyridinium chloride blocks herpes simplex virus replication in gingival fibroblasts" [Anti. Res. 179 (2020) 104818]
Antiviral Res. 2021 Feb 22:105022. doi: 10.1016/j.antiviral.2021.105022. Online ahead of print.NO ABSTRACTPMID:33627248 | DOI:10.1016/j.antiviral.2021.105022 (Source: Antiviral Research)
Source: Antiviral Research - February 25, 2021 Category: Virology Authors: Diana M Alvarez Luisa F Duarte Nicolas Corrales Patricio C Smith Pablo A Gonz ález Source Type: research

Corrigendum to "Cetylpyridinium chloride blocks herpes simplex virus replication in gingival fibroblasts" [Anti. Res. 179 (2020) 104818]
Antiviral Res. 2021 Feb 22:105022. doi: 10.1016/j.antiviral.2021.105022. Online ahead of print.NO ABSTRACTPMID:33627248 | DOI:10.1016/j.antiviral.2021.105022 (Source: Antiviral Research)
Source: Antiviral Research - February 25, 2021 Category: Virology Authors: Diana M Alvarez Luisa F Duarte Nicolas Corrales Patricio C Smith Pablo A Gonz ález Source Type: research